What are the main effects and indications of deuterated colexitinib?

Deucravacitinib is an oral small molecule targeted drug that is a tyrosine kinase 2 (TYK2) inhibitor. It was approved by the US FDA in 2022 for the treatment of adult patients with moderate to severe plaque psoriasis, especially for those patients who are suitable for systemic treatment or phototherapy. It is the world's first and currently only drug that selectively targets TYK2 and represents an important breakthrough in the oral treatment of psoriasis.

TYK2 is a member of the JAK family and plays a central role in a variety of immune signaling pathways, especially involved in the signal transduction of IL-23, IL-12 and type I interferon. These inflammatory pathways are highly related to the pathogenesis of psoriasis. Deuterocolexitinib blocks these signal transductions by targeting the regulatory region of TYK2 (pseudokinase domain), thereby inhibiting excessive activation of the immune system and achieving the effect of controlling skin lesions. Unlike traditional JAK inhibitors, it does not directly act on the active site of tyrosine kinase, thereby achieving a better balance between efficacy and safety.

In overseas phase III clinical trials, colexitinib performed significantly better than placebo and active control drugs, such as Apremilast, in improving PASI scores (Psoriasis Area and Severity Index) and sPGA scores (Static Physician Global Assessment). Most patients can observe significant improvement in their skin within 12 to 16 weeks of taking the medication, and some patients even achieve near-clearance effects. In addition, because it is a once-daily oral medication and does not require injection, it greatly improves patient compliance and treatment convenience compared with biological agents.

In general, the main effect of deuterated colexitinib is to precisely intervene in the inflammatory nature of psoriasis, significantly improve skin symptoms and delay the progression of the disease. Its indications are currently focused on adults with moderate to severe plaque psoriasis. It is a new option worth considering, especially for patients who are ineffective, unable to tolerate, or unwilling to undergo injection therapy for traditional systemic treatments.

Reference materials:https://go.drugbank.com/drugs/DB16650